Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Are FFR and IVUS Similar to Assess Intermediate Lesions?

In coronary artery disease (CAD), lumen area and plaque burden, characteristics and physiological impact are what define prognosis. 

¿El FFR y el IVUS son similares para evaluar las lesiones intermedias?

At present, coronary angiography continues to be the gold standard for CAD assessment. 

When considering PCI to treat intermediate lesions, FFR has been shown beneficial and safe. Not yet IVUS.

1682 patients with intermediate lesions (40 – 70% occlusion) in 2.5 mm vessels by visual estimation to be assessed with FFR or IVUS. 838 of these vessels were assessed with FFR (49.8%) and 844 with IVUS (50.2%).

Primary end point was a composite of all cause death, myocardial infarction and/or revascularization within 24 months after randomization. 

Mean age was 65, mostly men, 33% diabetic, 17% had kidney function deterioration, 6% prior MI, 20% PCI. Ejection fraction was 63%.

Read also: Gender Differences and 10-Year Prognosis in STEMI.

63% presented stable heart disease, 30% acute coronary syndrome, 1.6% NSTEMI and 0.5% STEMI.

The artery most frequently affected was the anterior descending (61%), 47% of patients presented only one vessel, and 32% two vessels. There were no differences in vessel diameter, lesion obstruction or length. 

In patients who underwent IVUS there were more angioplasty procedures (65.3% vs. 44.4%). 

Primary end point at 24 months was similar for both strategies (8.1% vs. 8.5% P=0.01 for non-inferiority)

Read also: Is TCA Useful for Severe Impairment of Left Ventricular Ejection Fraction?

Neither were there differences in all-cause mortality (4.6% vs. 3.4%), MI (1.9% vs. 1.7%), revascularization (5.7% vs. 5.3%) or stroke (0.7% vs. 1.2%) for FFR or IVUS respectively.

Conclusion

In patients with intermediate lesions assessed for PCI, FFR was non inferior to IVUS as regards primary end point evolution, the composite of death, MI or revascularization, at 24 months. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Fractional Flow Reserve or Intravascular Ultrasonography to Guide PCI. For the FLAVOUR Investigators. 

Reference: B.-K. Koo, et al. N Engl J Med 2022;387:779-89. DOI: 10.1056/NEJMoa2201546.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...